'''InNexus Biotechnology, Inc.''' is a drug company based in British Columbia, Canada, with principal management located in the Mayo Clinic MCCRB Building on the Mayo Clinic Campus in Scottsdale, Arizona, USA. InNexus was founded in 2001 and became a publicly traded corporation in 2003 on the Toronto Stock Exchange (TSX: IXS).

They are developing what they refer to as DXL-modified antibodies, wherein certain autophilic peptides are integrated with a monoclonal antibody. The DXL-modified antibodies have been shown to have enhanced binding affinity and, as a result, greater potency for use as an improved therapeutic to fight cancer and higher signal strength for use as an improved diagnostic for detecting cancer versus an unmodified antibody.

References

• "Study: DXL625 Cross-linking System Increases Treatment Potency", Hermatology & Oncology News, September 14, 2007, Accessed March 2, 2008.

• "InNexus Biotechnology Announces Preliminary Results of Animal Study Comparing Cancer Killing Activity of Its DXL625 (CD20) Treatment for Non-Hodgkin's Lymphoma With Leading Marketed Product", Reuters, February 7, 2008, Accessed March 2, 2008.

• "Maybach Financial Adds InNexus to Watchlist", Tradingmarkets.com, January 30, 2008, Accessed March 2, 2008.

• ?InNexus Named to TSX Venture Top 50?, TSX Venture Exchange Official Website, May 31, 2007, Accessed March 2, 2008.

• "Momentum Builds in Valley's Cancer Research Efforts", Phoenix Business Journal, November 23, 2007, Accessed March 2, 2008.

• ?InNexus Receiving Warm Welcome From Mayo Clinic?, Arizona Republic, September 25, 2006, Accessed March 2, 2008.